Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
$356.54M
Dr. Richard A. Miller M.D.
28.00
Burlingame, CA
Mar 23, 2016
-13.26
$-0.43
1.11
3.62
-9,193.50%
-14.52
0.27
6.41
1,398.50
3.62
-35.03%
-53.99%
Similar stocks (7)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
ETF Exposure (12)
iShares Micro-Cap ETF
IWC
0.04527%
Dimensional U.S. Core Equity 2 ETF
DFAC
3.473e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (7)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
ETF Exposure (12)
iShares Micro-Cap ETF
IWC
0.04527%
Dimensional U.S. Core Equity 2 ETF
DFAC
3.473e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%